- Home » News and EventsPage 10
NEWS & EVENTS
Our newest offerings and capabilities. Recent investments in network capacity, new and expanded services and expertise. Upcoming conferences and events.
Catalent Opens New Full-Service Clinical Supply Facility in Shiga, Japan
Oct 4, 2021
Catalent today announced the opening of its new clinical supply facility, strategically located in the Shiga prefecture of Japan, in response to increased demand for end-to-end services, including primary packaging and white glove services.
Catalent Signs Commercial Supply Agreement with Phathom Pharmaceuticals
Sep 16, 2021
Catalent today announced that it had signed a commercial supply agreement with Phathom Pharmaceuticals for its lead compound, vonoprazan, which is a novel, orally active-potassium competitive acid blocker (P-CAB).
Catalent to Extend Leadership in Rapidly Growing Nutraceuticals Market with Proposed $1 Billion Acquisition of Bettera, a Leading Gummies Manufacturer
Aug 30, 2021
Catalent today announced that it has reached an agreement to acquire Bettera Holdings, LLC, a major manufacturer in the high-growth gummy, soft chew, and lozenge segments of the nutritional supplements market, for $1 billion.
Catalent Appoints Harold Jenkins as General Manager of its Clinical Supply Facility in Philadelphia
Aug 12, 2021
Catalent today announced the appointment of Harold A. Jenkins III, as General Manager of its recently expanded Philadelphia facility, the company’s North American center of excellence for clinical supply packaging.
Catalent to Supply Edenbridge Pharmaceuticals with a Patient-Focused Fast-Dissolve Zydis® Formulation of Glycopyrrolate Intended for Use as Adjunctive Therapy in the Treatment of Patients with Peptic Ulcer
Aug 10, 2021
Catalent has signed a commercial supply agreement with Edenbridge Pharmaceuticals, for a novel formulation of glycopyrrolate using Catalent’s proprietary Zydis® orally disintegrating tablet (ODT) delivery technology intended for use as adjunctive therapy in the treatment of patients with peptic ulcer.
Catalent Achieves 97% Renewable Electricity Sourcing and Commits to Science-Based Target Initiative to Reduce Carbon Footprint
Aug 3, 2021
Catalent announced that, effective July 1, 2021, 97% of its electricity usage across its global network is being procured from renewable energy sources such as wind, solar, hydroelectric, and biomass.
DisperSol and Catalent Collaborate to Establish KinetiSol® Technology Manufacturing Hub for DisperSol Pharmaceutical Pipeline
Aug 2, 2021
DisperSol Technologies and Catalent today announced a strategic manufacturing collaboration to accelerate the development of multiple DisperSol pharmaceutical products.
Catalent Launches New OptiDose® Design Solution to Help Create Differentiated Treatments that are Successful for Innovators, Patients and Health Care Professionals
Jul 26, 2021
Catalent today announced the launch of its new OptiDose® Design Solution, a comprehensive assessment of your molecule, patient, and market, to help drive the dose design decision-making process and create successful treatments.
Catalent Biologics Launches New GPEx® Lightning Cell Line Expression Technology to Shorten Drug Substance Development Timelines by up to Three Months
Jul 22, 2021
Leveraging Catalent’s proven GPEx® expression platform in a glutamine synthase (GS) knock-out Chinese hamster ovary (CHO) cell line system, GPEx Lightning combines innovative technologies to further shorten drug substance development timelines.
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.